Question 1

What are the specific doses of capecitabine and docetaxel I would receive if I participate?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study to Assess Capecitabine (Xeloda®) in Patients With Locally Advanced or Metastatic Breast Cancer clinical trial (NCT00077857). Contact the study team or your healthcare provider for specific answers.

Question 2

How does this trial compare to other treatment options available to me?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study to Assess Capecitabine (Xeloda®) in Patients With Locally Advanced or Metastatic Breast Cancer clinical trial (NCT00077857). Contact the study team or your healthcare provider for specific answers.

Question 3

What side effects should I expect from these treatments?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study to Assess Capecitabine (Xeloda®) in Patients With Locally Advanced or Metastatic Breast Cancer clinical trial (NCT00077857). Contact the study team or your healthcare provider for specific answers.

Question 4

How often would I need to come in for treatments and check-ups?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study to Assess Capecitabine (Xeloda®) in Patients With Locally Advanced or Metastatic Breast Cancer clinical trial (NCT00077857). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if my cancer progresses while I am in the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study to Assess Capecitabine (Xeloda®) in Patients With Locally Advanced or Metastatic Breast Cancer clinical trial (NCT00077857). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any costs or travel requirements I should be aware of?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study to Assess Capecitabine (Xeloda®) in Patients With Locally Advanced or Metastatic Breast Cancer clinical trial (NCT00077857). Contact the study team or your healthcare provider for specific answers.

What this study is about